Christoph Rader
New York, New York, United States
1K followers
500+ connections
New York, New York, United States
1K followers
500+ connections
About
My area of expertise is antibody technologies including antibody discovery, antibody…
Activity
-
We are hiring, check out these job openings at Gyes.
We are hiring, check out these job openings at Gyes.
Liked by Christoph Rader
-
I am happy to announce that my PhD thesis defense will be next week on Tues August 27th at 12pm EST/9am PST! Thank you to all who helped me get to…
I am happy to announce that my PhD thesis defense will be next week on Tues August 27th at 12pm EST/9am PST! Thank you to all who helped me get to…
Liked by Christoph Rader
-
Bold science happens here. Today marks the official opening of the Lilly Seaport Innovation Center (LSC), our new state-of-the-art research and…
Bold science happens here. Today marks the official opening of the Lilly Seaport Innovation Center (LSC), our new state-of-the-art research and…
Liked by Christoph Rader
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
Zurich, Switzerland
-
-
Zurich, Switzerland
-
-
Bayreuth, Germany
Publications
-
[158] Sculpting a uniquely reactive cysteine residue for site-specific antibody conjugation
Bioconjugate Chemistry
-
[140] Generation and validation of structurally defined antibody-siRNA conjugates.
Nucleic Acids Research
-
[139] Chemically programmable and switchable CAR-T therapy.
Angewandte Chemie International Edition
-
[137] Bispecific antibodies in cancer immunotherapy.
Current Opinion in Biotechnology
-
[123] A Sortase A programmable phage display format for improved panning of Fab antibody libraries.
Journal of Molecular Biology
-
[120] Potent and selective antitumor activity of a T-cell engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Proceedings of the National Academy of Sciences of the United States of America
-
[115] Mining naïve rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility.
Journal of Molecular Biology
-
[113] Stable and potent selenomab-drug conjugates.
Cell Chemical Biology
More activity by Christoph
-
In our ChemRxiv manuscript, we present a chemoproteomic strategy for the de novo discovery of PROTAC degraders. Using comparative global proteomics…
In our ChemRxiv manuscript, we present a chemoproteomic strategy for the de novo discovery of PROTAC degraders. Using comparative global proteomics…
Liked by Christoph Rader
-
Karin Briner’s early interest and success in chemistry fueled her ambition to pursue drug discovery and develop life-saving medicines. Today, as our…
Karin Briner’s early interest and success in chemistry fueled her ambition to pursue drug discovery and develop life-saving medicines. Today, as our…
Liked by Christoph Rader
-
Adaptimmune has won FDA approval for its synovial sarcoma treatment Tecelra, the first engineered cell therapy for a solid tumor.
Adaptimmune has won FDA approval for its synovial sarcoma treatment Tecelra, the first engineered cell therapy for a solid tumor.
Liked by Christoph Rader
-
CAR-T Meets CAR-E, an Enhancer Platform to Prevent Cancer Relapse Relapse after CAR-T cell therapy could be prevented with the new CAR-E platform…
CAR-T Meets CAR-E, an Enhancer Platform to Prevent Cancer Relapse Relapse after CAR-T cell therapy could be prevented with the new CAR-E platform…
Liked by Christoph Rader
-
Absci Founder & CEO Sean McClain recently spoke with Luke Timmerman on the Long Run Podcast to discuss the origins of Absci, how our SynBio roots are…
Absci Founder & CEO Sean McClain recently spoke with Luke Timmerman on the Long Run Podcast to discuss the origins of Absci, how our SynBio roots are…
Liked by Christoph Rader
-
#TCR-directed #ADCs for treating #Cancers of #Tcells | Harald Kolmar & Co. throw an #Immunotherapy Lifeline to #Patients with this aggressive &…
#TCR-directed #ADCs for treating #Cancers of #Tcells | Harald Kolmar & Co. throw an #Immunotherapy Lifeline to #Patients with this aggressive &…
Liked by Christoph Rader
-
We’re excited to announce the publication of a potential breakthrough in the delivery of bispecific T cell engagers for oncology using B cell…
We’re excited to announce the publication of a potential breakthrough in the delivery of bispecific T cell engagers for oncology using B cell…
Liked by Christoph Rader
-
We are very excited to share our discovery chemistry story of MK-1084, an orally bioavailable and low-dose KRASG12C covalent inhibitor currently in…
We are very excited to share our discovery chemistry story of MK-1084, an orally bioavailable and low-dose KRASG12C covalent inhibitor currently in…
Liked by Christoph Rader
-
‘CD4+ T cells must engage with CD8+ T cells on the same dendritic cell during the effector phase, forming a three-cell-type cluster (triad) to…
‘CD4+ T cells must engage with CD8+ T cells on the same dendritic cell during the effector phase, forming a three-cell-type cluster (triad) to…
Liked by Christoph Rader
-
Happy 50th Birthday NAR! I was proud to publish my first paper with NAR in 1986 on the 3'thiolation of oligonucleotides with Ron Zuckermann and Peter…
Happy 50th Birthday NAR! I was proud to publish my first paper with NAR in 1986 on the 3'thiolation of oligonucleotides with Ron Zuckermann and Peter…
Liked by Christoph Rader
-
Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, is thrilled to announce that the newest…
Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, is thrilled to announce that the newest…
Liked by Christoph Rader
-
Congratulations to our portfolio company Marengo Therapeutics on a second strategic partnership with Ipsen to include up to two additional…
Congratulations to our portfolio company Marengo Therapeutics on a second strategic partnership with Ipsen to include up to two additional…
Liked by Christoph Rader
-
New #JITC article: Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma https://bit.ly/3yJ8fuy…
New #JITC article: Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma https://bit.ly/3yJ8fuy…
Liked by Christoph Rader
-
Rounding out the biggest graduation year in the lab's history and starting with my last Scripps Research graduate student, Patrick R Fitzgerald. We…
Rounding out the biggest graduation year in the lab's history and starting with my last Scripps Research graduate student, Patrick R Fitzgerald. We…
Liked by Christoph Rader
-
First EGFR inhibitor to show benefit in Stage III setting, extending progression-free survival by more than three years! #medicine…
First EGFR inhibitor to show benefit in Stage III setting, extending progression-free survival by more than three years! #medicine…
Liked by Christoph Rader
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Christoph Rader
2 others named Christoph Rader are on LinkedIn
See others named Christoph Rader